Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 675-681

  Komatsu, Tomoko ^a   Yamazaki, Hiroshi ^a   Shimada, Noriaki ^b   Nagayama, Sekio ^c   Kawaguchi, Yasuro ^c   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; CYTOCHROME P450; FLUOROURACIL; TEGAFUR; THYMIDINE PHOSPHORYLASE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER; LIVER CYTOSOL; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; PYRIDINES; TEGAFUR; THYMIDINE PHOSPHORYLASE; TIME FACTORS;

EID: 0034905292     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Results of treatment of malignant tumors with ftorafur
2. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil)
3. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
4. Metabolic activation of ftorafur [R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: The microsomal oxidative pathway
5. Metabolic activation of R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes
6. Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma
7. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil
8. Roles of cytochrome P450 IA2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anti-cancer prodrug, in human liver microsomes
9. Enzymatic formation of 5-fluorouracil from 1-(tertahydro-2-furanyl)-5-fluorouracil (tegafur) in human tumor tissues
10. Partial purification of a thymidine phosphorylase from human gastric cancer
11. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors
12. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues
13. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: Implications for chemotherapy with 5-fluoropyrimidines
14. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes
15. Formation of a dihydroxy metabolite of phenytoin by human liver microsomes/cytosol: Roles of cytochrome P450 2C9, 2C 19, and 3A4
16. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
17. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides
18. Determination of inorganic phosphate by coupling thymidine phosphorylase and reversed-phase high-performance liquid chromatography: Application to tonoplast pyrophosphatase activity
19. Protein measurement with the Folin phenol reagent
20. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
21. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil
22. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases
23. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
24. Effect of uracil on metabolism of 5-fluorouracil in vitro
25. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
26. Detection of a novel cytochrome P-450 IA2 polymorphism (F21L) in Chinese
27. Genetic polymorphism in the 5′-flanking region of human CYPIA2 gene: Effect on the CYP1A2 inducibility in humans
28. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis -3, 5- dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans
29. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans
30. Cytochrome P450 expression in oesophageal cancer
31. Enhanced expression of cytochrome P450 in stomach cancer
32. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
33. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy
34. Interferon suppresses erythromycin metabolism in rats and human subjects
35. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues
36. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
37. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5 fluorouridine by cyclophosphamide in mammary tumor models